miR-214 promotes apoptosis and sensitizes breast cancer cells to doxorubicin by targeting the RFWD2-p53 cascade

Biochemical and Biophysical Research Communications

Volumn 478, Issue 1, 2016, Pages 337-342

  Zhang, Jiaxuan ^a   Su, Beibei ^a   Gong, Chen ^a   Xi, Qingsongg ^a   Chao, Tengfei ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptosis; Breast cancer; Chemotherapy; miR 214; RFWD2

Indexed keywords

DOXORUBICIN; MICRORNA 214; PROTEIN P53; UBIQUITIN PROTEIN LIGASE COP1; UBIQUITIN PROTEIN LIGASE E3; ANTINEOPLASTIC ANTIBIOTIC; MICRORNA; MIRN214 MICRORNA, HUMAN; RFWD2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG SENSITIVITY; DRUG TARGETING; ECTOPIC EXPRESSION; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MCF 7 CELL LINE; PRIORITY JOURNAL; BREAST NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DOXORUBICIN; DRUG SYNERGISM; FEMALE; HUMANS; MICRORNAS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 84980360911     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.07.054     Document Type: Article

References (26)

1. [1] DeSantis, C., Ma, J., Bryan, L., Jemal, A., Breast cancer statistics, 2013. CA Cancer J. Clin. 64 (2014), 52–62.
2. [2] Zagouri, F., Sergentanis, T.N., Tsigginou, A., Dimitrakakis, C., Zografos, G.C., Dimopoulos, M.A., Psaltopoulou, T., Female breast cancer in Europe: statistics, diagnosis and treatment modalities. J. Thorac. Dis. 6 (2014), 589–590.
3. [3] Zeng, H., Zheng, R., Zhang, S., Zou, X., Chen, W., Female breast cancer statistics of 2010 in China: estimates based on data from 145 population-based cancer registries. J. Thorac. Dis. 6 (2014), 466–470.
4. [4] Sledge, G.W., Neuberg, D., Bernardo, P., Ingle, J.N., Martino, S., Rowinsky, E.K., Wood, W.C., Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J. Clin. Oncol. 21 (2003), 588–592.
5. [5] Li, X., Lewis, M.T., Huang, J., Gutierrez, C., Osborne, C.K., Wu, M.F., Hilsenbeck, S.G., Pavlick, A., Zhang, X., Chamness, G.C., Wong, H., Rosen, J., Chang, J.C., Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 100 (2008), 672–679.
6. [6] Magee, P., Shi, L., Garofalo, M., Role of microRNAs in chemoresistance. Ann. Transl. Med., 3, 2015, 332.
7. [7] Wang, J., Yang, M., Li, Y., Han, B., The role of MicroRNAs in the chemoresistance of breast Cancer. Drug Dev. Res. 76 (2015), 368–374.
8. [8] Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004), 281–297.
9. [9] Penna, E., Orso, F., Taverna, D., miR-214 as a key hub that controls cancer networks: small player, multiple functions. J. Invest Dermatol. 135 (2015), 960–969.
10. [10] Derfoul, A., Juan, A.H., Difilippantonio, M.J., Palanisamy, N., Ried, T., Sartorelli, V., Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis 32 (2011), 1607–1614.
11. [11] Yu, X., Luo, A., Liu, Y., Wang, S., Li, Y., Shi, W., Liu, Z., Qu, X., MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy. Mol. Cancer, 14, 2015, 208.
12. [12] Lowe, S.W., Ruley, H.E., Jacks, T., Housman, D.E., p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 (1993), 957–967.
13. [13] Dornan, D., Wertz, I., Shimizu, H., Arnott, D., Frantz, G.D., Dowd, P., O'Rourke, K., Koeppen, H., Dixit, V.M., The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429 (2004), 86–92.
14. [14] Dornan, D., Bheddah, S., Newton, K., Ince, W., Frantz, G.D., Dowd, P., Koeppen, H., Dixit, V.M., French, D.M., COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res. 64 (2004), 7226–7230.
15. [15] Chao, T.F., Xiong, H.H., Liu, W., Chen, Y., Zhang, J.X., MiR-21 mediates the radiation resistance of glioblastoma cells by regulating PDCD4 and hMSH2. J. Huazhong Univ. Sci. Technol. Med. Sci. 33 (2013), 525–529.
16. [16] Wang, W., Liao, P., Shen, M., Chen, T., Chen, Y., Li, Y., Lin, X., Ge, X., Wang, P., SCP1 regulates c-Myc stability and functions through dephosphorylating c-Myc Ser62. Oncogene 35 (2016), 491–500.
17. [17] Lewis, B.P., Burge, C.B., Bartel, D.P., Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120 (2005), 15–20.
18. [18] Wang, X., miRDB: a microRNA target prediction and functional annotation database with a wiki interface. RNA 14 (2008), 1012–1017.
19. [19] Wang, X., El Naqa, I.M., Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics 24 (2008), 325–332.
20. [20] Wang, F., Liu, M., Li, X., Tang, H., MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett. 587 (2013), 488–495.
21. [21] Yang, H., Kong, W., He, L., Zhao, J.J., O'Donnell, J.D., Wang, J., Wenham, R.M., Coppola, D., Kruk, P.A., Nicosia, S.V., Cheng, J.Q., MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68 (2008), 425–433.
22. [22] Yu, Z.W., Zhong, L.P., Ji, T., Zhang, P., Chen, W.T., Zhang, C.P., MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol. 46 (2010), 317–322.
23. [23] Levine, A.J., Momand, J., Finlay, C.A., The p53 tumour suppressor gene. Nature 351 (1991), 453–456.
24. [24] Borresen-Dale, A.L., TP53 and breast cancer. Hum. Mutat. 21 (2003), 292–300.
25. [25] Su, C.H., Zhao, R., Zhang, F., Qu, C., Chen, B., Feng, Y.H., Phan, L., Chen, J., Wang, H., Wang, H., Yeung, S.C., Lee, M.H., 14-3-3sigma exerts tumor-suppressor activity mediated by regulation of COP1 stability. Cancer Res. 71 (2011), 884–894.
26. [26] Lee, Y.H., Andersen, J.B., Song, H.T., Judge, A.D., Seo, D., Ishikawa, T., Marquardt, J.U., Kitade, M., Durkin, M.E., Raggi, C., Woo, H.G., Conner, E.A., Avital, I., Maclachlan, I., Factor, V.M., Thorgeirsson, S.S., Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma. Cancer Res. 70 (2010), 8264–8269.